SCHEMBL22925847

SCHEMBL22925847

O=C(NC[C@@H](O)CO)c1ccc(Nc2ncc(-c3ccc(C(F)(F)F)cc3)o2)nn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 9/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
DGAT1 O75907 1/20 0.37
PRMT5 O14744 1/20 0.36
FAAH O00519 2/20 0.35
KIT P10721 1/20 0.33
SCN9A Q15858 3/20 0.33
DYRK3 O43781 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CDK5 Q00535 1/20 0.33
DYRK1A Q13627 1/20 0.33
CDK5R1 Q15078 1/20 0.33
DYRK2 Q92630 1/20 0.33
DYRK1B Q9Y463 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620913 1.00 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1PRMT5
SCHEMBL28733621 1.00 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1PRMT5
SCHEMBL24636933 0.90 TRPV1 (0.39) TRPV1HDAC1HDAC6DGAT1FAAH
SCHEMBL22925675 0.86 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1
SCHEMBL22925985 0.86 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1
SCHEMBL29620976 0.86 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1
SCHEMBL22925988 0.86 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1
SCHEMBL29620979 0.86 TRPV1 (0.40) TRPV1HDAC1HDAC6DGAT1
SCHEMBL22925659 0.83 TRPV1 (0.45) TRPV1HDAC1HDAC6DGAT1
SCHEMBL29696299 0.83 TRPV1 (0.45) TRPV1HDAC1HDAC6DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB TRPV1 4690/4885HDAC1 19/4885HDAC6 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.